Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial

Introduction The PIONEER 7 trial demonstrated superior glycemic control and weight loss with once-daily oral semaglutide with flexible dose adjustment versus sitagliptin 100 mg in type 2 diabetes. This 52-week extension evaluated long-term oral semaglutide treatment and switching from sitagliptin to...

Full description

Bibliographic Details
Main Authors: Ann Mertens, John B Buse, Bruce W Bode, Young Min Cho, Erik Christiansen, Christin L Hertz, Morten A Nielsen, Thomas R Pieber
Format: Article
Language:English
Published: BMJ Publishing Group 2020-12-01
Series:BMJ Open Diabetes Research & Care
Online Access:https://drc.bmj.com/content/8/2/e001649.full

Internet

https://drc.bmj.com/content/8/2/e001649.full

Similar Items